Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool has positions in and ...

Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the ...

The Vikings may be best known for raiding and sailing, but now their eating habits are also drawing attention. The "Viking diet" — sometimes called the "Nordic diet" — is rooted in what Norse people ...

A second analyst voices positive thoughts on Viking's new GLP-1 weight loss drug. Phase 3 clinical trial data on VK2735 arrives later this year, and phase 2 data on a GLP-1 pill could come out as ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Americans may love to eat junk, but we’re nearly as passionate about doing penance, with more than half of us scarfing down dietary supplements on a regular basis. From herbal remedies to energy ...

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo ...

Based on a review of dozens of studies over the past four decades, researchers estimate that about 9% of adolescents in the general population have used over-the-counter weight-loss products in their ...